Skip to main content
Clinical Trials/KCT0006918
KCT0006918
Recruiting
未知

A prospective, non-interventional, multicenter, observational study to investigate the effectiveness and safety of Sevikar HCT® Tablet in hypertensive patients with type 2 diabetes mellitus or prediabetes in Korea

Daiichi-Sankyo Korea0 sites3,000 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the circulatory system
Sponsor
Daiichi-Sankyo Korea
Enrollment
3000
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Daiichi-Sankyo Korea

Eligibility Criteria

Inclusion Criteria

  • 1\. Hypertensive patient with T2DM or pre\-DM eligible to receive treatment with Sevikar HCT® tablet at the medical discretion of their treating physician. The diagnostic criteria of T2DM and pre\-DM in this study are complied with the criteria of The Korean Diabetes Association (2019\) as follows:
  • \- T2DM (at least one of the following)
  • 1\) HbA1c value is over 6\.5% or
  • 2\) Fasting glucose concentration (FGC) is greater than or equal to 126 mg/dL after at least 8 hours of fasting or
  • 3\) Plasma glucose concentration after 2 hours of 75g oral glucose tolerance test (OGTT) is greater than or equal to 200 mg/dL or
  • 4\) Plasma glucose concentration is greater than or equal to 200 mg/dL according to random plasma glucose test with typical symptoms of DM and hyperglycemia (Polyuria, polyphagia, weight loss of unknown cause)
  • \- Pre\-DM (at least one of the following)
  • 1\) Impaired fasting glucose (IFG): fasting plasma glucose concentration is 100\~125 mg/dL
  • 2\) Impaired glucose tolerance (IGT): Plasma glucose concentration after 2 hours of OGTT is 140\~199 mg/dL
  • 3\) HbA1c value is 5\.7\~6\.4%

Exclusion Criteria

  • 1\. Patients who have been prescribed Sevikar HCT® tablet within 3 months of entering the study
  • 2\. Patients determined to be ineligible for participation in this study at the discretion of the treating physician

Outcomes

Primary Outcomes

Not specified

Similar Trials